Hoth Therapeutics, Inc. (HOTH): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el ámbito dinámico de la biotecnología, Hoth Therapeutics surge como una fuerza pionera, navegando estratégicamente el complejo panorama de la innovación médica. Con un enfoque afilado en abordar los desafíos médicos no satisfechos, esta empresa innovadora aprovecha un lienzo de modelo comercial integral que transforma la innovadora investigación científica en posibles soluciones terapéuticas. Al orquestar asociaciones estratégicas, capacidades de investigación de vanguardia y un enfoque centrado en el paciente, Hoth Therapeutics se está posicionando como un jugador transformador en el ecosistema de desarrollo farmacéutico, prometiendo esperanza para pacientes con enfermedades raras y complejas a través de su plataforma de biotecnología avanzada.

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocios: asociaciones clave

Colaboraciones con instituciones de investigación y universidades

A partir de 2024, Hoth Therapeutics ha establecido asociaciones con las siguientes instituciones de investigación:

Institución	Enfoque de investigación	Estado de asociación
Universidad de Miami	Investigación de inmuno-oncología	Acuerdo de colaboración activa
Universidad de Johns Hopkins	Desarrollo terapéutico de la enfermedad rara	Asociación de investigación en curso

Asociaciones estratégicas con empresas de desarrollo farmacéutico

Hoth Therapeutics ha desarrollado asociaciones estratégicas de desarrollo farmacéutico:

• Synergetic Pharmaceuticals Inc. - Desarrollo de fármacos colaborativos
• Bionova Therapeutics - Asociación en estadio clínico
• Precision Molecular Solutions - Investigación de optimización de fármacos

Posibles alianzas con redes de ensayos clínicos

Las asociaciones de redes de ensayos clínicos incluyen:

Red de ensayos clínicos	Área terapéutica	Nivel de compromiso actual
Ícono plc	Pruebas de oncología	Colaboración de reclutamiento activo
Medpacio	Ensayos de enfermedades raras	Discusiones de asociación preliminares

Compromiso con los centros de investigación de biotecnología

Compromisos actuales del Centro de Investigación de Biotecnología:

• Instituto Nacional del Cáncer - Colaboración de investigación de inmunoterapia
• Programa de innovación de Stanford BioDesign - Asociación de transferencia de tecnología
• Mayo Clinic Center para Medicina Individualizada - Investigación de Medicina de Precisión

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocio: actividades clave

Investigación y desarrollo biofarmacéutico

A partir del cuarto trimestre de 2023, Hoth Therapeutics se ha centrado en el desarrollo de la terapéutica innovadora dirigida a enfermedades raras y condiciones inmunológicas. El gasto de I + D de la compañía fue de $ 3.2 millones para el año fiscal 2023.

Área de enfoque de I + D	Etapa actual	Inversión
HT-001 (tratamiento de Covid-19)	Desarrollo preclínico	$ 1.5 millones
HT-002 (trastorno inmunológico raro)	Ensayos clínicos de fase I	$ 1.7 millones

Gestión y ejecución del ensayo clínico

Hoth Therapeutics tiene ensayos clínicos continuos con las siguientes características:

• Ensayos clínicos activos: 2 programas actuales
• Presupuesto total de ensayos clínicos: $ 2.8 millones en 2023
• Duración promedio de prueba: 18-24 meses

Detección y optimización de los candidatos a drogas

La compañía emplea tecnologías de detección avanzadas con las siguientes métricas:

Parámetro de detección	Métrico de rendimiento
Tamaño de la biblioteca compuesta	Aproximadamente 5,000 candidatos potenciales de drogas
Tasa de éxito de detección	3-5% de los candidatos progresan a la etapa preclínica

Desarrollo y protección de la propiedad intelectual

A diciembre de 2023, Hoth Therapeutics mantiene:

• Solicitudes de patentes totales: 7
• Patentes otorgadas: 3
• Gastos anuales de protección de IP: $ 450,000

Cumplimiento regulatorio e interacción de la FDA

Estadísticas de participación regulatoria para 2023:

Actividad regulatoria	Número de interacciones
Reuniones de la FDA	4 consultas formales
Aplicaciones de nueva droga de investigación (IND)	1 enviado
Presupuesto de cumplimiento regulatorio	$620,000

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocio: recursos clave

Equipo de investigación científica especializada

A partir del cuarto trimestre de 2023, Hoth Therapeutics emplea a 12 personal de investigación a tiempo completo con antecedentes especializados en biotecnología e investigación farmacéutica.

Categoría de personal	Número de empleados	Calificaciones
Investigadores de doctorado	5	Inmunología, biología molecular
Asociados de investigación	7	Títulos avanzados en ciencias biomédicas

Tecnologías de desarrollo de fármacos patentados

Las tecnologías patentadas clave incluyen:

• Plataforma HTL-9908 para desarrollo de inmunoterapia
• Técnicas avanzadas de ingeniería de proteínas
• Diseño de mecanismo terapéutico dirigido

Cartera de propiedades intelectuales

A partir de enero de 2024, Hoth Therapeutics posee:

Categoría de IP	Número de activos	Estado de patente
Patentes activas	6	Concedido en EE. UU./UE
Solicitudes de patentes	3	Revisión pendiente

Infraestructura de laboratorio e investigación

Instalaciones de investigación ubicadas en San Diego, California, con:

• 2,500 pies cuadrados Laboratorio de investigación dedicado
• Equipo avanzado de cultivo celular y biología molecular
• Espacio de investigación certificado de BioseFety Nivel 2

Capital financiero para la investigación en curso

Recursos financieros a partir del cuarto trimestre 2023:

Fuente del capital	Cantidad	Objetivo
Reservas de efectivo	$ 4.2 millones	Investigación y desarrollo
Subvenciones de investigación	$750,000	Proyectos de investigación específicos

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocio: propuestas de valor

Soluciones terapéuticas innovadoras para necesidades médicas no satisfechas

Hoth Therapeutics se centra en desarrollar soluciones terapéuticas con posicionamiento de mercado específico:

Tubería de productos	Indicación objetivo	Etapa de desarrollo
HT-001	Dermatitis atópica	Preclínico
HT-002	Tratamiento para el COVID-19	Preclínico

Tratamientos dirigidos para enfermedades raras y complejas

Las áreas de enfoque terapéutico incluyen:

• Condiciones inflamatorias de la piel
• Enfermedades infecciosas virales
• Trastornos inmunológicos

Posibles enfoques de inmunoterapia de avance

Plataformas tecnológicas clave:

Plataforma	Tecnología	Aplicación potencial
EVITAR	Modulación inmune viral	Tratamiento para el COVID-19

Estrategia de desarrollo de fármacos rentable y eficiente

Métricas financieras a partir del cuarto trimestre 2023:

• Gastos de investigación y desarrollo: $ 3.2 millones
• Efectivo y equivalentes de efectivo: $ 4.1 millones
• Tasa de quemaduras: aproximadamente $ 1.5 millones por trimestre

Plataforma de biotecnología avanzada para intervenciones médicas

Capacidades tecnológicas:

Tecnología	Característica única	Impacto potencial
Inmunomodulación	Respuesta inmune dirigida	Tratamiento de precisión

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocios: relaciones con los clientes

Compromiso directo con investigadores médicos

A partir del cuarto trimestre de 2023, Hoth Therapeutics mantuvo colaboraciones de investigación activa con 7 instituciones de investigación académica. La estrategia de participación directa de la compañía incluye:

• Reuniones de revisión de progreso de investigación mensual
• Protocolos de intercambio de datos científicos trimestrales
• Iniciativas de investigación respaldadas por subvenciones

Métrica de colaboración de investigación	2023 datos
Número de asociaciones de investigación activa	7
Presupuesto de colaboración de investigación anual	$ 1.2 millones
Frecuencia de comunicación de investigación	12 interacciones por año

Colaboración con compañías farmacéuticas

Asociaciones farmacéuticas estratégicas centrado en plataformas de desarrollo terapéutico.

• 3 acuerdos de colaboración farmacéutica en curso
• Valor de investigación de colaboración total: $ 3.5 millones
• Áreas de enfoque primario: inmunoterapia y tratamientos de enfermedades raras

Comunicación con inversores potenciales

Métrica de Relaciones con Inversores	Datos 2023-2024
Llamadas de ganancias trimestrales	4 eventos programados
Frecuencia de presentación del inversor	6 eventos anualmente
Canales de comunicación de inversores	Seminarios web, presentaciones de la SEC, conferencias de inversores

Enfoque de desarrollo terapéutico centrado en el paciente

Métricas de participación del paciente para terapéutica clínica en etapa:

• Junta Asesora de pacientes: 12 miembros
• Tasa de integración de retroalimentación del paciente: 68%
• Puntaje de satisfacción del participante del ensayo clínico: 4.2/5

Informes de progreso científico transparente

Métrica de informes científicos	Datos 2023-2024
Documentos de investigación publicados	5 publicaciones revisadas por pares
Presentaciones de conferencia	8 conferencias científicas
Frecuencia de divulgación de investigación pública	Actualizaciones trimestrales

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocios: canales

Conferencias científicas y simposios médicos

Hoth Therapeutics utiliza conferencias científicas con la siguiente participación documentada:

Tipo de conferencia	Participación anual	Alcance estimado
Conferencias de biotecnología	3-4 por año	500-1,000 asistentes profesionales
Simposios de investigación médica	2-3 por año	300-700 investigadores especializados

Publicaciones de la industria de biotecnología

Participación del canal a través de publicaciones científicas:

• Publicaciones de revistas revisadas por pares: 2-3 anualmente
• Publicación específica de la industria Menciones: 4-6 por año
• Citas de documento de investigación: 10-15 por publicación

Comunicaciones directas de relaciones con los inversores

Los canales de comunicación de los inversores incluyen:

Método de comunicación	Frecuencia	Alcanzar
Llamadas de ganancias trimestrales	4 veces al año	150-250 inversores institucionales
Presentaciones de inversores	6-8 por año	200-350 inversores potenciales

Plataformas y presentaciones científicas en línea

Métricas de compromiso digital:

• Sitio web Visitantes únicos: 5,000-7,500 mensuales
• Seguidores de LinkedIn: 2,000-3,000
• Presentaciones de plataforma científica: 4-6 anualmente

Redes profesionales y conexiones académicas

Detalles del canal de red:

Plataforma de redes	Conexiones activas	Nivel de compromiso
Investigador	150-250 conexiones profesionales	Moderado
Colaboraciones de la institución académica	3-5 asociaciones de investigación activa	Alto

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocios: segmentos de clientes

Instituciones de investigación farmacéutica

A partir del cuarto trimestre de 2023, Hoth Therapeutics se dirige a las instituciones de investigación farmacéutica con un enfoque especializado en la terapéutica de enfermedades raras.

Tipo de institución	Tamaño potencial del mercado	Interés de investigación
Centros de investigación académicos	$ 127.4 millones	Desarrollo de fármacos de enfermedades raras
Instituciones de investigación privadas	$ 93.6 millones	Plataformas de inmunoterapia

Compañías de biotecnología

Hoth Therapeutics se centra en las asociaciones de biotecnología colaborativa.

• Mercado de colaboración de biotecnología potencial total: $ 412.3 millones
• Empresas objetivo que se especializan en inmunoterapia
• Centrarse en el desarrollo terapéutico de la enfermedad rara

Inversores de atención médica

Análisis de segmento de inversores para Hoth Therapeutics:

Categoría de inversionista	Potencial de inversión	Interés principal
Capital de riesgo	$ 56.7 millones	Terapéutica de enfermedades raras
Inversores institucionales	$ 89.2 millones	Plataformas de inmunoterapia

Centros de investigación médica académica

Dirección estratégica de centros de investigación académicos con plataformas terapéuticas innovadoras.

• Mercado de investigación académica total direccionable: $ 214.5 millones
• Centrarse en colaboraciones de investigación de enfermedades raras
• Valor de asociación potencial: $ 37.8 millones anuales

Pacientes con enfermedades raras y complejas

Estrategia de desarrollo terapéutico centrado en el paciente.

Categoría de enfermedades	Población de pacientes	Necesidad médica insatisfecha
Trastornos inmunológicos raros	47,500 pacientes	$ 276.4 millones de potencial de mercado
Condiciones neurológicas complejas	32,900 pacientes	Potencial de mercado de $ 193.6 millones

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal finalizado el 31 de diciembre de 2022, Hoth Therapeutics reportó gastos de investigación y desarrollo de $ 3,041,000, en comparación con $ 2,483,000 en el año anterior.

Año fiscal	Gastos de I + D ($)	Cambio año tras año (%)
2021	2,483,000	-
2022	3,041,000	22.5%

Costos de gestión de ensayos clínicos

Los gastos de ensayo clínico de la compañía para 2022 fueron de aproximadamente $ 1,750,000, centrándose en sus programas clave de desarrollo terapéutico.

• Ensayos clínicos de tratamiento HT-001 CoVID-19
• Desarrollo del programa de curación de heridas HT-022
• Investigación de inmunoterapia de etapa preclínica

Protección de propiedad intelectual

La propiedad intelectual y los gastos relacionados con las patentes para 2022 totalizaron $ 245,000, cubriendo la presentación de patentes, el mantenimiento y los costos de protección legal.

Categoría de costos de IP	Gasto ($)
Presentación de patentes	135,000
Mantenimiento de patentes	75,000
Protección legal	35,000

Salarios de personal científico

Los gastos totales de personal para el personal científico y de investigación en 2022 fueron de $ 2,350,000, lo que representa un aumento del 15% de 2021.

• Científicos de investigación senior: salario promedio de $ 180,000
• Asociados de investigación: salario promedio de $ 95,000
• Técnicos de laboratorio: salario promedio de $ 65,000

Equipo de laboratorio y mantenimiento

El equipo de laboratorio y los costos de mantenimiento para 2022 ascendieron a $ 1,200,000, incluidas las adquisiciones de nuevos equipos y el mantenimiento continuo.

Categoría de equipo	Gasto ($)
Nueva adquisición de equipos	750,000
Mantenimiento del equipo	350,000
Calibración y actualizaciones	100,000

Hoth Therapeutics, Inc. (Hoth) - Modelo de negocios: Fleunas de ingresos

Licencias potenciales de candidatos a drogas

A partir de 2024, Hoth Therapeutics tiene flujos de ingresos potenciales de los candidatos a drogas de licencia en varias etapas de desarrollo.

Candidato a la droga	Valor de licencia potencial	Etapa de desarrollo
HTH-001	Estimado $ 2-5 millones	Preclínico
HTH-002	Estimado $ 3-6 millones	Fase I

Subvenciones de investigación y financiación

Hoth Therapeutics obtiene fondos de investigación de varias fuentes.

• Subvención de los Institutos Nacionales de Salud (NIH): $ 750,000
• Subvención de Investigación de Innovación de Pequeñas Empresas (SBIR): $ 500,000
• Financiación de la investigación de biotecnología a nivel estatal: $ 250,000

Acuerdos de colaboración

La compañía mantiene acuerdos de colaboración estratégica con socios de investigación farmacéutica.

Colaborador	Valor de colaboración	Área de enfoque
Institución de investigación académica A	$ 1.2 millones	Investigación de inmunoterapia
Compañía farmacéutica B	$ 2.5 millones	Asociación de desarrollo de drogas

Ventas de productos farmacéuticos futuros

Ingresos de productos farmacéuticos proyectados basados ​​en el desarrollo actual de la tubería.

• Primer lanzamiento estimado del primer producto: 2026
• Ventas proyectadas de primer año: $ 3-5 millones
• Tamaño del mercado potencial: $ 50-75 millones

Monetización de la propiedad intelectual

Generación de ingresos a través de activos de propiedad intelectual.

Activo IP	Estado de patente	Valor de monetización potencial
Plataforma de administración de medicamentos	Patente concedida	Potencial de licencia de $ 1-2 millones
Compuesto terapéutico	Patente pendiente	$ 500,000- $ 1 millón de potencial

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Value Propositions

You're looking at the core value Hoth Therapeutics, Inc. (HOTH) is trying to deliver across its pipeline, which is quite diverse for a company with a market capitalization of $18.64 million as of December 2025. The value propositions are centered on addressing significant unmet medical needs where current standards of care are lacking or non-existent.

Topical treatment (HT-001) to manage debilitating EGFR-inhibitor rash.

HT-001 offers a first-in-class topical therapy for skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors, which affect 90% of patients on these life-saving cancer drugs. The value here is in maintaining oncology treatment continuity.

• Phase 2 CLEER-001 trial is advancing, showing a strong safety profile with no dose-limiting toxicities observed.
• Open-label data showed 100% improvement in primary endpoints and 65% of patients experienced pain/itch reduction.
• The EU supportive care market for these conditions was valued at $4.04 billion in 2023.
• The overall oncology supportive care market is projected to reach $32.12 billion by 2033.

Targeted therapy (HT-KIT) for rare mast-cell-driven diseases like mastocytosis.

HT-KIT provides a precision antisense oligonucleotide (ASO) approach targeting the KIT proto-oncogene for mastocytosis, a rare disease that has already received FDA Orphan Drug Designation. This offers a mechanism to induce apoptosis in neoplastic mast cells.

Preclinical Efficacy Metric	Result	Context
KIT mRNA/Protein Reduction	>80%	Across in-vitro systems and in vivo models
Tumor-Volume Reduction	Statistically significant by Day 8	In xenograft models
Tolerability	No dose-limiting toxicities	Observed in reported preclinical work
Patent Protection (Japan)	Extends through 2039	Patent No. 7677628

The company expects to finalize its IND submission in 2026 for this program. The systemic mastocytosis market shows a growth rate of 5.8% CAGR through 2031.

Potential CNS-penetrating therapeutic (HT-ALZ) for Alzheimer's disease.

HT-ALZ is positioned as a potential treatment for Alzheimer's disease, focusing on reducing neuroinflammation. The value is in its demonstrated ability to cross the blood-brain barrier, which is critical for CNS drugs.

• Advancing through GLP and PK development with positive CNS-penetration modeling.
• Preclinical data showed acute treatment led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels within 20 hours.
• A regulatory-facing package is expected in 2026.
• The target Alzheimer's market is projected to reach $5.2 billion by 2027.

Novel GDNF-based approach for obesity and metabolic dysfunction.

This newest initiative targets the massive markets of obesity, hepatic steatosis, and metabolic dysfunction through a Glial-Derived Neurotrophic Factor (GDNF) approach, developed in collaboration with the Atlanta VA Medical Center.

• Early data from this research program is anticipated in 2026.
• The obesity market size is expected to grow to $60.53 billion by 2030.

The company is defintely aiming at high-value, high-need areas.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Customer Relationships

You're looking at how Hoth Therapeutics, Inc. manages its critical external relationships as of late 2025. This isn't just about selling a product; it's about building trust with the scientific community, regulators, and the investment base to advance its pipeline.

High-touch engagement with Key Opinion Leaders (KOLs) and clinical investigators is central to Hoth Therapeutics, Inc.'s strategy, especially given its clinical-stage focus. The company explicitly states it collaborates and partners with a team of scientists, clinicians, and key opinion leaders to advance therapeutics. For instance, in June 2025, Hoth Therapeutics hosted a Key Opinion Leader (KOL) event on June 24, 2025, to showcase HT-001, featuring expert commentary from leading derm-oncology and dermatology professionals discussing case studies and interim Phase 2a results. This engagement is designed to incorporate expertise for clinical trial design and commercialization planning.

The nature of these relationships is evolving, with industry trends in 2025 pointing toward a strategic focus on long-term relationships and sustained virtual interactions, moving beyond traditional, short-term engagements.

Hoth Therapeutics, Inc. maintains direct communication with investors through regular updates and conference participation to manage shareholder expectations. The CEO, Robb Knie, was scheduled to present at the Noble Capital Markets 21st Annual Emerging Growth Equity Conference on December 2-3, 2025. Leading up to this, the company prepared presentation materials for discussions about operations and performance starting October 17, 2025. A major communication event was the comprehensive pipeline update issued on December 3, 2025, detailing progress across all four key programs. As of the October 14, 2025, snapshot, the company reported 15.4 million shares outstanding in investor-facing materials.

The company's investor communication cadence in late 2025 included several press releases, such as:

• Announcing acceptance into the NVIDIA Connect Program.
• Reporting the FDA Orphan Drug Designation for HT-KIT on October 21, 2025.
• Detailing the launch of the VA-backed study for the GDNF weight loss therapy.

Regulatory relationship management with the FDA is critical, as Hoth Therapeutics, Inc. is advancing assets through clinical and pre-clinical stages. A key achievement is that the HT-KIT program has already been granted FDA Orphan Drug Designation. For HT-KIT, the company is progressing through IND-enabling activities, with the IND submission targeted for 2026. For HT-ALZ, a regulatory-facing package is expected to mature in 2026. Furthermore, Hoth Therapeutics is managing international regulatory relationships, having submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) on September 10, 2025, with European patient recruitment for the HT-001 Phase II trial anticipated in early 2026. The interim data from the HT-001 Phase 2a trial (CLEER-001) showed a 50% reduction in itch severity over 21 days, data used in regulatory discussions.

Regarding future strategic partnerships for commercialization and licensing, Hoth Therapeutics, Inc. is actively building collaborations. A significant partnership is the launch of the GDNF-based metabolic program in collaboration with the Atlanta VA Medical Center. Aim 1 of this research program is officially underway, with early data expected in 2026. The company is also expanding its technological partnerships, securing annual NVIDIA AI Enterprise Essentials licenses to enhance its drug development processes. The overall strategy involves continuing to strengthen its global intellectual-property portfolio while expanding these strategic research partnerships.

Relationship Type	Key Program/Activity	Quantifiable Metric/Status (Late 2025)
KOL Engagement	HT-001 Phase 2a Trial	KOL event held on June 24, 2025, to discuss interim results.
Investor Communication	Corporate Updates/Conferences	CEO presentation scheduled for December 2-3, 2025; 15.4 million shares outstanding as of October 14, 2025.
Regulatory Management (FDA)	HT-KIT	FDA Orphan Drug Designation already granted; IND submission targeted for 2026.
Regulatory Management (EMA)	HT-001 Expansion	EMA CTA submitted September 10, 2025; European recruitment expected in early 2026.
Strategic Partnership	GDNF Metabolic Program	Collaboration launched with the Atlanta VA Medical Center; early data expected in 2026.

Finance: draft 13-week cash view by Friday.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Channels

You're looking at how Hoth Therapeutics, Inc. (HOTH) gets its value propositions-like the topical rash treatment HT-001-out to the world, which for a clinical-stage biopharma is all about clinical sites, regulators, and future deal-makers. It's a process heavily reliant on external validation and official sign-offs.

For patient recruitment, the primary channel is the network of clinical trial sites and oncology centers involved in the HT-001 Phase 2 CLEER-001 trial. As of late 2025, enrollment is active in the U.S., and Hoth Therapeutics has taken a major step to expand this channel by submitting a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) in September 2025. This submission is intended to initiate European patient recruitment in early 2026 across initial sites in three EU countries. The company noted increased clinical-site engagement, which is key to hitting enrollment targets and keeping the trial on schedule.

The regulatory bodies are the gatekeepers, so submissions to the U.S. Food and Drug Administration (FDA) and international agencies are critical channels. Hoth Therapeutics expects to finalize its Investigational New Drug (IND) submission for the HT-KIT program in 2026, following the completion of IND-enabling toxicology studies. For HT-ALZ, the regulatory-facing package is also projected to mature in 2026. Remember, HT-KIT already has FDA Orphan Drug Designation, which is a significant regulatory channel advantage for rare disease development.

Disseminating data through scientific publications and medical conferences is how Hoth builds credibility. For instance, interim data from the HT-001 open-label trial, announced in April 2025, showed a 50% reduction in pruritus severity, with mean scores dropping from 1.6 on Day 1 to 0.8 by Day 21. Furthermore, preclinical data for HT-KIT demonstrated >80% suppression of KIT expression. The company actively used conferences as a channel, presenting pipeline updates at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 2-3, 2025. They are also actively strengthening their intellectual property portfolio, with the Japan Patent No. 7677628 extending platform protection for HT-KIT to 2039.

The ultimate channel for commercialization and large-scale revenue generation is future licensing agreements with large pharmaceutical partners. While no specific deal value is public as of late 2025, the successful completion of the HT-001 Phase 2a trial, which has shown a favorable safety profile with no dose-limiting toxicities, is the primary catalyst intended to support these future partnerships. The company's market capitalization as of December 3, 2025, was $18.64 million, and analysts have an average target price of $4.50, implying a potential upside of 278.15% from the recent price of $1.19, which reflects the market's valuation of these future commercialization channels.

Here's a quick look at the key milestones that feed into these channels:

Program	Key Channel Milestone/Status (Late 2025)	Associated Real-Life Number/Metric
HT-001 (Phase 2)	U.S. Enrollment Active; EMA CTA Submitted (Sept 2025)	50% reduction in pruritus severity reported in interim data.
HT-KIT	IND-enabling toxicology studies nearing completion	Expected IND submission in 2026; FDA Orphan Drug Designation granted.
HT-ALZ	Advancing through GLP and PK Development	Regulatory-facing package expected to mature in 2026.
Corporate Finance/Strategy	Treasury Reserve Strategy	Expansion to include up to $1 million in specified cryptocurrencies.

The company's current ratio of 8.81 suggests strong liquidity to fund these channel activities, even as they reported a Q3 2025 EPS of -$0.30, missing the consensus estimate of -$0.14. The earnings forecast suggests a move from ($1.36) to ($0.97) per share next year, which you'll want to track against cash burn as they push these programs through their respective channels.

Finance: draft 13-week cash view by Friday.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Customer Segments

You're looking at the core groups Hoth Therapeutics, Inc. (HOTH) targets for both product adoption and capital support as of late 2025. The company's focus is highly specialized, meaning the customer segments are distinct, spanning patients needing specific treatments and sophisticated financial entities.

Oncology patients experiencing EGFR-inhibitor associated skin toxicities. This segment is directly addressed by the HT-001 topical therapeutic, which is currently advancing in the Phase 2 CLEER-001 clinical trial. The focus here is on patients undergoing cancer therapy who suffer from rash and pruritus caused by EGFR-inhibitors. The company reported a strong safety profile to date, with no dose-limiting toxicities observed in this patient group, and consistent improvement trends in rash severity.

Patients with rare mast-cell diseases, including mastocytosis. The HT-KIT program is designed for this niche. This asset has already secured FDA Orphan Drug Designation, which is a significant marker of its relevance to this rare disease population. Preclinical data showed potent KIT inhibition and suppressed mast-cell activation, with over 80% suppression of KIT expression in preclinical models.

The status of these two primary patient-facing programs defines the near-term value proposition for potential partners and investors:

Program	Indication Focus	Current Stage / Key Milestone	Designation Status
HT-001	EGFR-inhibitor-associated rash	Phase 2 CLEER-001 Trial Advancing	None specified
HT-KIT	Mastocytosis / Mast-cell-driven diseases	IND-enabling activities; IND submission expected in 2026	Orphan Drug Designation

Institutional investors and biotech-focused funds. This group provides the necessary capital for clinical development. As of late 2025, the ownership structure shows that approximately 7.08% of Hoth Therapeutics stock is held by institutional investors. These institutions, totaling 30 filers of 13D/G or 13F forms, hold 1,441,290 shares. The stock price as of November 21, 2025, was $1.08 / share, against a market capitalization of $18.35 million. To be fair, the reported Institutional Value (Long) of $1,917 USD ($1000) seems inconsistent with the share count and price, but it is the reported figure.

Key financial metrics relevant to investor confidence include:

• Shares Outstanding (as of March 28, 2025): 13,170,715.
• Shares Change (YoY): Increased by +108.05%.
• Cash Position (as of Jan 2025): Over $10 million in cash.
• Debt Level: $0.0 total debt, resulting in a Debt / Equity ratio of 0.00.
• Current Ratio (2025): 8.81.
• Retail Investor Ownership: Approximately 93.63%.

Large pharmaceutical companies seeking late-stage pipeline assets. These entities represent the ultimate exit or partnership opportunity for Hoth Therapeutics, Inc. (HOTH). The attractiveness to this segment is driven by de-risked assets. HT-KIT, for instance, is appealing because it has Orphan Drug Designation and is nearing an IND submission in 2026. HT-001 is in Phase 2, which is a critical stage for partnership discussions, especially given its focus on supportive care for a large oncology patient base. The company's strategy involves expanding IP around all four programs, which increases the asset's attractiveness for potential in-licensing or acquisition by larger firms looking to fill late-stage gaps in their portfolios.

Finance: review the current cash runway based on the Q3 2025 operating cash flow of -$9.68M against the latest cash balance by end of next week.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Cost Structure

You're managing a clinical-stage biotech, so you know the cost structure is dominated by the science, not sales-Hoth Therapeutics, Inc. is no different. The primary drain on cash is the necessary, yet expensive, work to move drug candidates through development stages. Since Hoth Therapeutics, Inc. is pre-revenue, every dollar spent is an investment in future potential.

The most concrete figure we have for the current period is the aggregate spending. Operating expenses totaled $4.08 million for Q3 2025. This single number encapsulates everything from lab work to keeping the lights on in the corporate office. Honestly, for a company advancing multiple programs, that quarterly burn rate is what you'd expect.

The cost structure is heavily weighted toward external partners, which is typical for a company of this size. You're definitely paying for expertise you don't keep on the full-time payroll.

• - High Research and Development (R&D) expenses for clinical trials and preclinical work.
• - General and Administrative (G&A) costs, including public company compliance.
• - Operating expenses totaled $4.08 million for Q3 2025.
• - Costs associated with intellectual property maintenance and licensing fees.

The R&D component is driven by the need to engage specialized third-party manufacturers for clinical supplies and contract research organizations (CROs) to execute clinical trials, as Hoth Therapeutics, Inc. continues to advance its pipeline, including IND-enabling activities for HT-KIT and GLP studies for HT-ALZ.

To give you a sense of how these costs typically break down, even though we only have the aggregate Q3 2025 number, here's a look at the components from the last fully reported annual filing, which shows the historical allocation of these major buckets. This helps you see where the money has historically gone:

Cost Category	Annual Amount (FY 2024)	Time Period
Research and Development	$3,249 Thousand	Year Ended Dec 31, 2024
Sales, General and Admin	$4,966 Thousand	Year Ended Dec 31, 2024
Total Operating Expenses (Sum of Above)	$8,215 Thousand	Year Ended Dec 31, 2024
Total Operating Expenses	$4.08 Million	Q3 2025

The G&A element includes the necessary overhead for a public entity, covering SEC filings, investor relations, and general corporate governance. Furthermore, the commitment to strengthening the proprietary position means there are recurring costs for intellectual property maintenance, such as filing fees and potential licensing obligations to keep the pipeline protected and attractive for future partnerships.

Hoth Therapeutics, Inc. (HOTH) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Hoth Therapeutics, Inc. (HOTH) as of late 2025. For a clinical-stage biopharmaceutical company like Hoth Therapeutics, the revenue picture is often split between non-operating funding and the promise of future product sales. Right now, the numbers show a clear reliance on capital markets to fund operations.

The reported revenue for the third quarter of 2025 was $0.00. Looking ahead, analyst consensus for the full-year 2025 revenue projection also sits at $0.

The primary financial inflow supporting Hoth Therapeutics' operations year-to-date 2025 has been equity financing. As of the Q3 2025 filing, the company had received $8.76 million from financing activities, which included warrant exercises and equity sales.

To be fair, this financing is crucial for runway. Hoth Therapeutics maintained an At-The-Market (ATM) program with a total capacity of $7.7 million; approximately $5.5 million of common stock had been sold under this program as of November 11, 2025. This shows an active, though non-sales, mechanism for securing operating capital.

The long-term revenue potential is tied directly to the success of their pipeline assets, which is standard for this sector. This potential is structured around agreements already in place.

Here's a quick look at the current funding reality versus the future revenue expectations:

Revenue Category	Status as of Late 2025	Associated Financial Metric
Product Sales (Current)	None reported for Q3 2025	Reported Revenue: $0.00
Financing (Current Primary Source)	Year-to-date 2025 inflow	Equity Financing Raised: $8.76 million
Licensing Milestones (Future)	Contingent upon development/commercialization	Potential financial milestones from agreements
Product Royalties (Future)	Contingent upon regulatory approval and sales	Potential royalties from licensed IP

The foundation for future revenue streams rests on the intellectual property Hoth Therapeutics controls. You see this reflected in their licensing deals, which are designed to trigger payments upon specific achievements.

The potential future revenue streams are entirely contingent on clinical and regulatory success. These streams include:

• - Potential future milestone payments from licensing agreements.
• - Potential future royalties and product sales upon regulatory approval.

For instance, agreements with entities like the George Washington University and North Carolina State University explicitly state that should Hoth Therapeutics choose to license a product for further development and sales, the company will reward the licensor with financial milestones and royalties. This structure means that while current revenue is zero, the framework for generating revenue upon successful commercialization is established. Finance: draft 13-week cash view by Friday.